aTyr Pharma, Inc.

Performance Summary

aTyr Pharma reported a net loss of $74.1 million for fiscal year 2025, with minimal revenue of $190 thousand. The company's loss from operations was $77.6 million, driven by total operating expenses of $77.8 million. Research and development expenses accounted for $60.2 million of this total, while general and administrative expenses were $17.6 million. The company's accumulated deficit increased to $606.2 million as of December 31, 2025. Total assets were $93.0 million, with current assets of $80.2 million including cash and cash equivalents of $10.7 million and available-for-sale investments of $67.9 million. Total liabilities were $25.7 million, resulting in stockholders' equity of $67.3 million.

Revenue Analysis

The company generated only $190 thousand in total revenues for fiscal year 2025. The document does not provide segment breakdowns or geographic revenue mix. The minimal revenue reflects the company's clinical-stage status with no commercial products. The company's collaboration with Kyorin Pharmaceutical in Japan has generated $20.0 million in upfront and milestone payments to date, with potential for up to $155.0 million in additional milestone payments and tiered royalties on future net sales in Japan.

Margins & Profitability

With minimal revenue of $190 thousand and operating expenses of $77.8 million, the company operated at a significant loss. The loss from operations was $77.6 million, representing essentially all of the net loss of $74.1 million after accounting for other income of $3.5 million. The company's cost structure is dominated by research and development expenses, which accounted for 77% of total operating expenses. General and administrative expenses represented the remaining 23% of operating costs.

Cash Flow & Balance Sheet

Net cash used in operating activities was $62.0 million for fiscal year 2025. Cash flows from investing activities used $5.1 million, primarily for purchases of available-for-sale investment securities. Cash flows from financing activities provided $66.0 million, mainly from at-the-market offerings of common stock. The net change in cash, cash equivalents and restricted cash was a decrease of $1.0 million. As of December 31, 2025, the company had cash, cash equivalents and restricted cash of $13.1 million, plus available-for-sale investments of $67.9 million, totaling $81.0 million in liquid assets. Total current liabilities were $15.1 million, resulting in a current ratio of approximately 5.3:1.

Outlook

The company expects to continue incurring net losses for the foreseeable future. Management believes current cash, cash equivalents, restricted cash and available-for-sale investments of $80.9 million will be sufficient to meet material cash requirements for at least one year. The company's ability to fund longer-term operating needs depends on raising additional funding through equity or debt offerings, grant funding, collaborations, strategic partnerships, and/or licensing arrangements. The company has scheduled a Type C meeting with the FDA in mid-April 2026 to review results of the EFZO-FIT study and determine the path forward for efzofitimod in pulmonary sarcoidosis. The company also expects to complete enrollment of the EFZO-CONNECT study in SSc-ILD in the first half of 2026.